Risks and benefits of phase 1 oncology trials, revisited

Razelle Kurzrock; Robert S. Benjamin

doi:10.1056/NEJMe058007

Risks and benefits of phase 1 oncology trials, revisited

Razelle Kurzrock, Robert S. Benjamin

Sarcoma Medical Oncology

Research output: Contribution to journal › Editorial › peer-review

77 Scopus citations

Original language	English (US)
Pages (from-to)	930-932
Number of pages	3
Journal	New England Journal of Medicine
Volume	352
Issue number	9
DOIs	https://doi.org/10.1056/NEJMe058007
State	Published - Mar 3 2005

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMe058007

Cite this

@article{7aa8d4789a064c92bbac214ef6d850f2,

title = "Risks and benefits of phase 1 oncology trials, revisited",

author = "Razelle Kurzrock and Benjamin, {Robert S.}",

year = "2005",

month = mar,

day = "3",

doi = "10.1056/NEJMe058007",

language = "English (US)",

volume = "352",

pages = "930--932",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "9",

}

TY - JOUR

T1 - Risks and benefits of phase 1 oncology trials, revisited

AU - Kurzrock, Razelle

AU - Benjamin, Robert S.

PY - 2005/3/3

Y1 - 2005/3/3

UR - http://www.scopus.com/inward/record.url?scp=14544286345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544286345&partnerID=8YFLogxK

U2 - 10.1056/NEJMe058007

DO - 10.1056/NEJMe058007

M3 - Editorial

C2 - 15745986

AN - SCOPUS:14544286345

SN - 0028-4793

VL - 352

SP - 930

EP - 932

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 9

ER -

Risks and benefits of phase 1 oncology trials, revisited

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this